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Abstract
Gene set analysis methods, which consider predefined groups of genes in the analysis of
genomic data, have been successfully applied for analyzing gene expression data in cross-
sectional studies. The time-course gene set analysis (TcGSA) introduced here is an exten-
sion of gene set analysis to longitudinal data. The proposed method relies on random
effects modeling with maximum likelihood estimates. It allows to use all available repeated
measurements while dealing with unbalanced data due to missing at random (MAR) mea-
surements. TcGSA is a hypothesis driven method that identifies a priori defined gene sets
with significant expression variations over time, taking into account the potential heteroge-
neity of expression within gene sets. When biological conditions are compared, the method
indicates if the time patterns of gene sets significantly differ according to these conditions.
The interest of the method is illustrated by its application to two real life datasets: an HIV
therapeutic vaccine trial (DALIA-1 trial), and data from a recent study on influenza and
pneumococcal vaccines. In the DALIA-1 trial TcGSA revealed a significant change in gene
expression over time within 69 gene sets during vaccination, while a standard univariate
individual gene analysis corrected for multiple testing as well as a standard a Gene Set
Enrichment Analysis (GSEA) for time series both failed to detect any significant pattern
change over time. When applied to the second illustrative data set, TcGSA allowed the
identification of 4 gene sets finally found to be linked with the influenza vaccine too although
they were found to be associated to the pneumococcal vaccine only in previous analyses.
In our simulation study TcGSA exhibits good statistical properties, and an increased power
compared to other approaches for analyzing time-course expression patterns of gene sets.
The method is made available for the community through an R package.
Author Summary
Gene set analysis methods use prior biological knowledge to analyze gene expression data.
This prior knowledge takes the form of predefined groups of genes, linked through their
biological function. Gene set analysis methods have been successfully applied in
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transversal studies, their results being more sensitive and interpretable than those of meth-
ods investigating genomic data one gene at a time. The time-course gene set analysis
(TcGSA) introduced here is an extension of such gene set analysis to longitudinal data.
This method identifies a priori defined groups of genes whose expression is not stable over
time, taking into account the potential heterogeneity between patients and between genes.
When biological conditions are compared, it identifies the gene sets that have different
expression dynamics according to these conditions. Data from 2 studies are analyzed: data
from an HIV therapeutic vaccine trial, and data from a recent study on influenza and
pneumococcal vaccines. In both cases, TcGSA provided new insights compared to stan-
dard approaches thanks to an increased sensitivity compared to other approaches. Those
results highlight the benefits of the TcGSA method for analyzing gene expression
dynamics.
This is a PLOS Computational BiologyMethods paper.
Introduction
Microarray experiments are increasingly used for evaluating changes in gene expression over
time. The analysis of the temporal change of gene expression should help in understanding the
complex mechanisms of gene regulation. For instance, transcriptional profiles have been
repeatedly measured to study the change in gene expression during the natural history of SIV/
HIV infection [1, 2] or to evaluate the effect of vaccines [3, 4]. In the applications considered in
this paper [5, 6], the investigators wanted to detect the genes for which the abundance changed
over time after a vaccination (against HIV, influenza or pneumococcus).
In order to analyze such longitudinal high-dimensional data, several approaches have been
suggested including a gene-by-gene statistical analysis [7, 8], dimension reduction methods [9]
or gene set analysis [10]. A gene set is a group of genes that are a priori co-regulated or func-
tionally linked. Examples of such gene set relating to biological processes or pathways are those
defined by KEGG [11], Gene Ontology [12] or Chaussabel’s functional modules [13]. The gene
set analysis [14–16] is supposed to be more powerful than a gene-by-gene analysis because it
can detect a change of expression of a group of genes although none of them show a very high
absolute fold change. Furthermore, a change of all genes in a given pathway may be biologically
more meaningful than a large increase of a single gene. Also, provided that the gene sets are
well defined, the result should be more sound and comparable across studies than a gene-by-
gene analysis [14]. Finally, gene set analysis avoids a second step for a global interpretation as
described in the “bottom up” approach [10, 17].
The analysis of longitudinal microarray experiments through a gene set approach is not triv-
ial because the dynamics of gene expressions inside a gene set can be complex and heteroge-
neous. This has already been underlined in some of the approaches developed to analyze gene
sets [15, 18–20]. Fig 1 shows an example of a homogeneous gene set, whereas Fig 2 shows an
example of a heterogeneous one. Actually, such a heterogeneity is frequently observed [20],
and cannot be ignored, as genes inside a functional gene set are not expected to change their
expression synchronously. Moreover this heterogeneity can be biologically meaningful by itself.
Prieto et al. [21] provide an example from a cancer application, where deregulated pathways
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are of primary biological interest. They identified heterogeneous gene sets linked to acute pro-
myelocytic leukemia. Another example is given by Hu et al.: pathways affected by the HER2,
such as the KEGG pathways of ‘Ubiquitin mediated proteolysis’, ‘Glioma’, and ‘Prostate cancer’
were identified by studying heterogeneity [22]. The main advantage of detecting the heteroge-
neity inside a gene set is to detect any change over time whatever the specification of the model
for the trends. In other words, the dynamics of gene expression inside a stable gene set will be
summarized by a flat slope and no heterogeneity. Hence, in the spirit of [19], to find any
significant change of the overall expression of genes inside a gene set over time, we suggest to
look for any significant trend over time or any heterogeneity between gene trends inside the
gene set.
Several approaches have already been proposed to analyze longitudinal measurements of
gene expression [7, 23–28], but only a few include gene set analysis [10, 18, 29–31]. Among the
latter, all but Nueda et al. [18] fail to account for possible heterogeneity inside a gene set. An
extension of the popular Gene Set Enrichment Analysis (GSEA) method [14] is available for
the analysis of time series data: GSEA for time series. Unfortunately, it does not account for the
structure of longitudinal data, simply treating all observations as independent and calculating
Pearson correlation of the genes with the time variable. Therefore this is quite a limited model-
ing strategy for longitudinal data. The globalANCOVA procedure developed by Hummel et al.
[29] focuses on the comparison of groups, testing whether there is a group influence on change
Fig 1. Example of a homogeneous gene set (M1.2: interferon—from the DALIA trial, after treatment
interruption). Each line is the median expression of a gene inside this particular gene set across all the
patients. The expression of the genes inside this gene set is quite homogeneous and it is easy to identify a
global time trend, displayed by the dashed black line (smoothed median). For more information see the
presentation of the DALIA-trial in the “Results” section.
doi:10.1371/journal.pcbi.1004310.g001
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over time of any gene expression inside a gene set. In practice, the global null hypothesis tested
is quite flexible relying on the ANOVA framework, but cannot accommodate missing values.
Wang et al. [10] proposed to use a linear mixed effects model to explain gene expression inside
a gene set. They considered a random effect for the array level rather than for the patient or the
gene level. Zhang et al. [30] proposed a robust non-parametric approach to compare gene
expression dynamics between different treatment-groups. Wu et al. [31] proposed the CAM-
ERA procedure, a gene set test based on linear modeling that takes into account inter-gene cor-
relations. However, CAMERA accounts for neither potential heterogeneity inside a gene set
nor for repeated measurement correlation. Of note, it is not possible to look at the change of
gene expression in only one group using Zhang et al. [30] approach. In contrast, the PCA-
maSigFun procedure developed by Nueda et al. [18, 32] can account for possible heterogeneity
inside a gene set. It is based on a Principal Component Analysis (PCA) of each gene set fol-
lowed by a linear regression of the significant principal components (i.e. components that have
a variation above the mean gene variance) over time. However, they did not consider time-
course experiments where repeated measures are available for multiple patient.
Gene set analysis methods can also be distinguished by their choice of the null hypothesis.
Those can be classified into two main types of hypothesis: i) the competitive null hypothesis,
that tests the genes inside a given gene set against all the other genes outside the gene set; ii) the
Fig 2. Example of a heterogeneous gene set (M4.16: cell cycle—from the DALIA trial, after treatment
interruption). Each line is the median expression of a gene inside this particular gene set across all the
patients. The expression of the genes inside this gene set is rather heterogeneous. This makes it difficult to
identify any time trend, as the mean expression inside this gene set stays close to zero. However a closer
look reveals two distinct time trends, displayed by the two respectively dashed and dotted black lines
(smoothed medians). For more information see the presentation of the DALIA-trial in the “Results” section.
doi:10.1371/journal.pcbi.1004310.g002
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self-contained null hypothesis, that only uses the genes inside the gene set of interest [20, 33,
34]. In the present paper, interest is focused on self-contained null hypotheses because the
question was “Which gene sets have a change of gene abundance over time?”. According to
Emmert-Streib et al. [35], self-contained gene set tests are biologically easier to interpret and
can be more powerful compared to competitive tests. Self-contained gene set tests are especially
appropriate in a hypothesis driven context where a priori defined gene sets are validated and
relevant regarding the biological question.
We propose the implementation of a hypothesis driven method that directly tests the time-
course significance of predefined gene sets: the Time-course Gene Set Analysis (TcGSA). It
relies on the use of linear mixed effect models, a very useful and well established statistical tool
[36, 37] especially suited for longitudinal settings. By using all available repeated measures, it
provides increased statistical power. TcGSA can accommodate for heterogeneity of gene
expression within the gene sets through random effects, and is robust to unbalanced designed
due to missing (at random) values thanks to the maximum likelihood estimates. No previously
proposed approach combines all of TcGSA features. A simulation study demonstrated the
good statistical performance of the proposed method. It has been applied to two studies: one
HIV vaccine trial, and one influenza and pneumoccocal vaccine study [6], using the same defi-
nition of gene sets [13] that is increasingly used in systems immunology research [38–42].
Compared to gene-by-gene analyses, TcGSA disclosed changes of additional gene sets that
endorse previous conclusions [6], but also revealed common pathways across the three
vaccines.
Methods
Time-course gene set analysis
The TcGSA method includes three steps: 1) modeling gene expression in a gene set with mixed
models, 2) testing the significance of a gene set, and 3) estimating individual gene profiles.
1. Modeling gene expression in a gene set with mixed models. Let S be a gene set of
interest. We start by the case of a one group experiment, where each patient act as her/his own
respective control, her/his condition changing over time. The expression of genes inside S is
modeled over time according to a function f as:
for all the genes g 2 S,
ygpi ¼ mþ bg þ cgp þ fgðtiÞ þ εgpi ð1Þ
where ygpi is expression of the g
th gene for the pth patient at the ith time, μ is the intercept in the
gene set S, βg is the fixed effect of the g
th gene, cgp *N(0, σc) is a random effect grouped by the
gth gene of the pth patient, ti is the i
th measurement time, εgpi *N(0, σ) is an error term. Finally
fg(ti) is a function of time, that can be linear, polynomials, etc. Every time coefficient of the
trend fg(ti) is actually divided into a fixed effect η (representing the average trend in the gene
set S) and a random effect hg,*N(0, σh) grouped on the gene g, accounting for the possible
heterogeneity between the genes in the gene set S. In this paper we focus on three forms for fg
(but other forms, such as exponential, etc. could easily be envisaged):
• linear polynomials:
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• natural cubic splines:
fgðtÞ ¼
PKþ1
k¼1 Zk þ hg;k
 
NkðtÞ
where the Nk(t) form the natural cubic splines basis [43] for the time variable t (with K internal
knots), η are the fixed effects of time shared across the gene set S, and hg, are the random
effects of time accounting for possible heterogeneity between genes. (hg,1,. . ., hg, d)*N(0,Sh)
with d being the degree of the time function, and for k = 1,. . ., d hg, k *N(0, σhk). Alternatively,
one can make the assumption that the patient effect is the same for all the genes. In that case,
the random effect c is no longer grouped on the gene level, and the model can be written as:
for all the genes g 2 S,
ygpi ¼ mþ b
0
g þ c0p þ fgðtiÞ þ εgpi ð1bisÞ
with c0p  N ð0; sc0 Þ the random effect of the patient p, and b0g  N ð0; sb0 Þ the random effect of
the gene g. This alternative modeling has the advantage to be more parsimonious than the Eq
(1), with less parameters to be estimated.
Let’s now consider the case of a multiple group experiment (such as treatment/vaccine
groups for instance). The expression of genes inside S is modeled over time according to a func-
tion fg, m that is now stratified on the groups:
for all the genes g 2 S,
ymgpi ¼ mþ bg þ dm þ cgp þ fg;mðtiÞ þ εgpi ð2Þ
wherem indicates which group is concerned and δm is the fixed intercept of them
th group,
everything else being the same as in the Eq (1).
2. Testing the significance of a gene set. In TcGSA, a “significant” gene set is a gene set
whose expression is not stable either over time (in one group experiments) or over groups (in
several groups experiments), once between genes and patients variability is taken into account.
In other words, we want to test the significance of the time trend while being sensitive to both
homogeneous and heterogeneous changes of gene expression over time inside a gene set. Test-
ing the significance of a given gene set S therefore means testing both fixed and random effects
at once, in a single test. A likelihood ratio test is the natural way to do so, fitting models under
both the null hypothesis and the alternative.
In the case of one group experiment (Eqs (1) and (1bis)) the null hypothesis (H0) is that the
genes inside S are stable over time, i.e. that their expressions are constant and homogeneous
over time (all coefficients of the function of time f are not significantly different from zero).
The alternative hypothesis (H1) is that the genes inside S vary significantly over time:
ðH0Þ : 8 k; Zk ¼ 0 and shk ¼ 0 ð1:0Þ
ðH1Þ : 9 k; Zk 6¼ 0 or shk 6¼ 0 ð1:1Þ
In the case of a multiple group experiment (Eq (2)), the null hypothesis is that inside the
gene set S, the evolution of gene expressions over time is the same regardless of the group. The
alternative hypothesis is that time trends f are different depending on the groupm:
ðH0Þ : 8m; fg;mðÞ ¼ fgðÞ ð2:0Þ
ðH1Þ : 9m; m0 such that fg;mðÞ 6¼ fg;m0 ðÞ ð2:1Þ
Time-Course Gene Set Analysis
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In both case, one model is fitted under the null hypothesis, and one is fitted under the alter-
native. The likelihood ratio is then computed.
However, since both fixed and random effects are tested simultaneously in this likelihood
ratio, its null distribution is not the standard chi-square distribution (because of boundary con-
straints due to the variance of random effects). According to Self et al. [44], it can be approxi-








where q is the number of fixed effects and r the number of random effects to be tested simulta-
neously. This approximation implies that the tested random effects are independent of one
another [45–47]. This seems an acceptable assumption according to our simulations under the
null (see S1 and S2 Figs). This allows to compute a p-value for the significance of the variation
of a given gene set over time.
When several gene sets are investigated at a time, it is necessary to take into account multi-
ple testing. A number of procedures are available to do so [48]. As the TcGSA is mostly an
exploratory analysis (even though hypothesis driven in the sense that gene set are defined a pri-
ori), we recommend using the Benjamini-Yekutieli procedure for controlling the False Discov-
ery Rate [49], as gene sets are necessarily correlated between each others and this procedure is
robust to some of these dependances. Other mutliple testing correction procedures are avail-
able in the TcGSA R package.
3. Estimation of individual gene profiles. In the estimation of linear mixed model, it is
common to use the Restricted Maximum Likelihood (REML) instead of the classic Maximum
Likelihood (ML) in order to avoid biased estimates of the variance components [50]. But note
that REML cannot be used to estimate the likelihood ratios presented here. Indeed, REML esti-
mation of the likelihood ratio between two models can only be used when both models have
the same fixed part [51]. Since here the compared models (under H0 and under H1) have differ-
ent fixed components (due to the η coefficients under H1), the use of ML estimation is needed.
For the inference of the random effects, Best Linear Unbiased Predictor (BLUP) are used
[52], giving access to estimations of a single profile for each gene among a gene set, in each
patient. As a result, the estimations from the mixed model are shrunken towards the average
expression inside the gene set. This shrinkage occurs when the residuals variability is relatively
large compared to the the random effects estimated variances [52]. The mixed model uses the
repeated pattern of the longitudinal measurements to structure the variation. Its estimations
give smoother trajectories for the genes than the raw data, which makes the general evolution
of the set clearer [53], as it can be seen in Figs 3 and 4.
Characterization and visualization of dynamics
Dynamic of a significant gene set. Once a gene set S has been identified as significant
through the previous mixed likelihood ratio statistics, a summary of its dynamic over time is
needed. However, due to the possible heterogeneity of S, giving a summary representation of S
dynamic is not obvious. We propose to automatically identify the number of trends in a signifi-
cant gene set from the fit of the model. Predicted gene expressions from the linear mixed
model are clustered, and the optimal number of trends is selected with the gap statistic [54]. It
is a formalization of the elbow criterion for the within-cluster variance. In order to determine
the optimal partition of each gene set here, the gap statistics is applied onto a hierarchical clus-
tering of gene expressions inside each gene set. Then the median within each of the identified
clusters can summarize each trend. Therefore, gene sets are actually split when heterogeneous,
Time-Course Gene Set Analysis
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before being summarized. The predicted gene expression from the linear mixed model is used
for this (and not the observed expression) because smoothness of trajectories facilitates classifi-
cation [53]. Examples of such representations are given in Figs 3 and 4.
Global dynamics. Most often, TcGSA will be used to investigate a large number of gene
sets (from a few hundreds to a few thousands). This multiplicity can make visualization of the
results more challenging, in addition of requiring a multiple testing correction. TcGSA is
designed to identify gene sets that shows a simultaneous evolution of gene expression, but pos-
sibly of a small intensity. The method can therefore be quite sensitive, and it can be of interest
to rank the significant gene sets to identify the most acute signals. The likelihood ratio provides
insight on the magnitude of the variation of each gene set. The percentile of their correspond-
ing likelihood ratio gives an idea of the importance of the variation for a significant gene set.
Examples of such representations are given in Fig 5.
Implementation
The TcGSA method has been implemented in R as a package TcGSA, whose latest release is
available from the CRAN repository (http://cran.r-project.org/web/packages/TcGSA/index.
html).
Results
Motivating example: The DALIA-1 trial
The DALIA-1 trial is a phase 1 therapeutic HIV vaccine trial whose details are described on
http://clinicaltrials.gov (ClinicalTrial.gov identifier: NCT00796770) and in [5]. The vaccine
candidate was based on ex-vivo generated interferon-α dendritic cells loaded with HIV-1 lipo-
peptides and activated with lipopolysaccharide. The objectives of the trial were to evaluate the
safety of the strategy and to evaluate the immune response to the vaccine. For the purpose of
the present paper, we focus on the gene expression component of this study. Gene abundance
in whole blood was measured through Illumina HumanHT-12 v4 Expression BeadChips.
The DALIA-1 trial design. All of the nineteen HIV infected patients received the thera-
peutic vaccine while under antiretroviral treatment. The patients received four injections at
week 0, 4, 8 and 12. This vaccination period was followed by an antiretroviral treatment inter-
ruption (ATI) at week 24. The patients were followed up to week 48. Antiretroviral treatment
was resumed from week 24 to week 48 at any time under the following criteria: i) if the patients
or their doctors wished so; ii) if CD4+ T-cell count was< 350 cells/μL and< 25% of total lym-
phocytes. Fourteen time points (five in pre-ATI from week 0 to week 22, and nine in post-ATI
from week 24 to week 44) were used for this analysis (see Fig 6). One patient was removed
from the analysis as his/her antiretroviral treatment compliance was irregular during the vacci-
nation phase.
In the following analysis, two distinct datasets were considered: pre-ATI and post-ATI. The
two datasets were normalized separately—via a normal-exponential convolution model [55,
56], followed by the application of the ComBatmethod [57] to correct for batch effects.
Fig 3. Three significant gene sets during pre-ATI in DALIA-1. Each line is the median over the patients of the expression of one gene. Each graph shows
all the genes in one particular gene set. The left graph displays the raw gene expression, the right one displays the estimations from the mixed model for the
same gene set. The expressions have been centered and reduced for this representation.
doi:10.1371/journal.pcbi.1004310.g003
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Fig 4. Ten significant gene sets during post-ATI in DALIA-1. Each line is the median over the patients of the expression of one gene. Each graph shows
all the genes in one particular gene set. The left graph displays the raw gene expression, the right one displays the estimations from the mixed model for the
Time-Course Gene Set Analysis
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Splitting the data allows us to study separately the vaccine effect and the treatment interrup-
tion, otherwise the ATI effect would mask any noticeable vaccine effect, because of the huge
modification of gene expression related to viral replication [1, 2]. We investigated the gene sets
defined by Chaussabel et al. [13], which are oriented towards the immune system. The defini-
tion and annotations of those 260 gene sets (called ‘Modules’) are available online (http://www.
biir.net/public_wikis/module_annotation/V2_Trial_8_Modules).
Pre-ATI: The vaccination phase. During the vaccination period, a standard gene-by-gene
mixed model analysis, with a cubic polynomial function of time, did not found any significant
change of gene abundance at a 5% False Discovery Rate (see Table 1). However, during this
vaccination phase, cytokines production analysis of the same blood samples (as measured by
Luminex or intracellular staining) have showed that a response was induced by the vaccine at
week 16 [5]. Therefore, one expected to observe a signal at the gene expression level between
week 0 and week 16, the gene expression preceding molecular activation. Although the mea-
surements were not performed in the hours or days following vaccination, the changes of gene
abundance may reflect a change of the equilibrium of the overall expression in some gene sets.
This kind of results has already been reported in cross-sectional studies [58]. Likewise, GSEA
for time-series did not identify any significant gene set during vaccination. This can be
explained by the lack of power of GSEA for time-series, as this method does not take into
account the repeated structure of the data and is not suitable for longitudinal measurements.
Finally, CAMERA did not identified any significant gene set either, in spite of testing a compet-
itive null hypothesis.
We applied the Time Course Gene set Analysis (see Methods) that allows to detect any
change over time of gene abundance inside a gene set by detecting either trends over time or
heterogeneity between gene dynamics. Fitting the Eq (1) with a cubic polynomial function of
time, 69 gene sets out of 260 turned out to vary significantly. Fig 3 displays the raw sample-nor-
malized and batch-corrected) and estimated gene expressions of 3 of the significant gene sets
identified by TcGSA: T-cell, inflammation and B-cell gene sets. The identification of gene sets
such as M4.1: T-cell (that includes CD402, CCR7, BCl2) was expected with regards to the CD4
T-cell response observed at Week 16 [5]. Also, the gene sets M4.6: inflammation and M6.7: B-
cell are good examples of how smoothing from the estimations can give a much clearer
dynamic pattern compared to the raw expression (see Methods).
Post-ATI: After antiretroviral treatment interruption. Eq (1) was then fitted to the data
after antiretroviral treatment interruption that occurred at week 24: 216 gene sets out of 260
were found to be significant with a cubic polynomial function of time. Fig 4 displays the raw
and estimated expressions of nine of those significant gene sets. It features heterogeneous gene
sets, such as M4.16 and M7.1, which are both also good examples of the shrinkage that occurs
with the estimations (see Methods). Meanwhile, GSEA for time series identifies 67 significant,
whereas CAMERA identified only 2. These results are consistent with the lower statistical
power found in our simulation study.
The large number of significant gene sets post-ATI illustrates the tremendous impact of the
treatment interruption on the organism. Followed by a viral rebound, the treatment interrup-
tion is indeed a major event that triggers the expression of thousand of genes. Indeed, a gene-
by-gene analysis revealed 3,389 significant probes (more than 10% of all the investigated
same gene set. If several dynamics are identified by the gap statistics among the estimated expressions inside one gene set, they are displayed in different
colors—such as for the gene sets M 4.16 and M 7.1 that each features three different dynamics. The expressions have been centered and reduced for this
representation.
doi:10.1371/journal.pcbi.1004310.g004
Time-Course Gene Set Analysis
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probes—an unusually high number of differentially expressed genes). The immune system is
very much in demand during the viral rebound. Therefore most of the gene sets from the Mod-
ules defined by Chaussabel et al. [13] are activated, as they are tightly linked with the immune
system activity. Of particular interest are the three gene sets M1.2, M3.4 and M5.12 which are
all annotated as interferon-related. These three gene sets exhibit similar dynamics (see Fig 4).
Such a timely upregulation was expected, as it is associated to the viral rebound after treatment
interruption and was previously reported [1, 2]. The gene set M3.4 is also linked with antiviral
response.
Fig 5. Heatmap of estimated dynamics from the significant gene sets among the 62 investigated gene sets when comparing vaccines arms to
placebo arm. The median estimated gene expression over the patients is used for each trend. Each trend has seen its values reduced (so that its variance is
1) in order to make the dynamics more comparable. Each row is a group of gene having the same trend inside a gene set, and each column is a time point.
The color key represents the median of the standardized estimation of gene expression over the patients for a given trend in a significant gene set. It
becomes red as median expression is up-regulated or blue as it is down-regulated compared to the value in the placebo (saline) at the same time. A and C
show the hierarchically clustered trends for pneumoccocal and flu respectively. B and D show the same trends but instead ranked by decreasing likelihood
ratio percentiles of the associated gene set, for pneumoccocal and flu respectively.
doi:10.1371/journal.pcbi.1004310.g005
Fig 6. DALIA-1 trial design.Gene expression was measured at each time point, represented by a week number above the time axis. The trial was
composed of two separated stages: (1) the treatment phase, during which the patients were vaccinated but remained under antiretroviral treatment; and(2)
the follow- up phase commencing after the week 24 antiretroviral treatment interruption. Those two phases will be referred as pre-ATI and post-ATI
respectively. The three apheresis time points were removed from the analysis due to a possible effect of the apheresis on the gene expression samples, and
so was the first measurement (week -8) occurring right at the inclusion in the study.
doi:10.1371/journal.pcbi.1004310.g006
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Another application: Influenza and pneumococcal vaccines responses
In a recent paper, Obermoser et al. [6] investigated the response to influenza and pneumococ-
cal vaccines in healthy individuals at the gene expression level.
Study design. Healthy, young adults were randomly split in three groups of six volunteers
each, receiving either a 2009–2010 seasonal influenza vaccine (Fluzone), a 23-valent pneumo-
coccal vaccine (Pneumovax23), or a placebo (saline injections). Blood samples were collected
at days -7, 0, 1, 3, 7, 10, 14, 21, and 28 to measure gene expression in whole blood. A more
detailed description of the study can be found in Obermoser et al. [6].
Original analysis. In their modular analysis, Obermoser et al. [6] focused on 62 of the 260
available gene sets defined in Chaussabel et al. [13]. They investigated the changes of gene
expression in those 62 gene sets for each of the seven time points from day 1 to day 28 in
regards of the baseline, that was considered as the average of the two measurements at days -7
and 0. So hierarchical structure of the data was not taken into account. The three arms (saline,
flu and pneumococcal) were analyzed separately, and only significant gene sets at day 1 and
day 7 (not further on) are presented in their paper. Changes in eight gene sets were common to
both vaccines: M4.6 (inflammation), M6.6 and M6.13 (apoptosis/cell death) and modules
M4.1 and M4.15 (T cells), M4.3 (protein synthesis), M5.11, and M6.9 (no functional annota-
tion). Nine gene sets were uniquely changing after the influenza vaccine, three were associated
with antiviral responses (M1.2, M3.4, M5.12) and included genes coding for interferon (IFN)-
inducible molecules. Six gene sets were uniquely responsive to the pneumococcal vaccine. Of
these, five were modules including genes associated with inflammation: M3.2, M4.2, M4.13,
M5.1 and M5.7.
TcGSA results. To compare the gene expression at the gene set level between the vaccine
arm (flu or pneumococcal) and the placebo (saline) arm, we applied TcGSA on these data
using Eq (2) (for each vaccine separately). In both vaccines, a large response is observed at Day
1. To avoid smoothing down the expression at ti = 1, we used the following function of time to
model the dynamic evolution of gene expression:
fmðtiÞ ¼ ðZm þ hgÞ1fti¼1g þ ðZ0m þ h0gÞ1fti 6¼1g
with ðhg ; h0gÞ  N ð0;ShÞ, andm the group (either vaccine or placebo).
Most of the 62 investigated gene sets presented a significantly different evolution in vaccine
arms compared to the placebo arm. Globally, the intensity of the response was stronger with
Table 1. Number of significant units in DALIA-1 at a FDR of 5%.
Pre-ATI Post-ATI Units
Gene-by-gene 0 3,389 probes a
GSEA for time series 0 67 genes set b
CAMERA 0 2 genes set b
TcGSA linear 23 203 gene sets b
TcGSA cubic polynom. 69 216 gene sets b
TcGSA splines 68 219 gene sets b
a 32,978 probes investigated after filtering
b 260 immune-related gene sets investigated (29 gene sets were automatically discarded because less
than 10 probes were observed)
doi:10.1371/journal.pcbi.1004310.t001
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the pneumoccocal vaccine than with the flu vaccine (Fig 5). The early response induced by the
pneumococcal vaccine was dominated by inflammation whereas the top signal triggered by the
flu vaccine involved an interferon signature (Fig 5B and 5D). In both vaccine, a T-cell response
was also visible. In the pneumoccocal vaccine, a plasma cell signal, in association with cell cycle
gene sets (Figs 5A and 5C), started at Day 7 until Day 14. This plasma blast signal was much
less clear in the flu vaccine (Figs 5B and 5D). This is in agreement with the results of Obermo-
ser et al. modular analysis.
TcGSA offers an extended and appropriate hierarchical analysis of these data. It provides a
truly longitudinal insight into the vaccine responses, that are intrinsically compared to the pla-
cebo response. One of the main difference from the results presented in Obermoser et al. paper
[6] is that, according to our analysis, the inflammation gene sets (M3.2, M4.13, M5.1 and
M5.7) were also involved with the flu vaccine and were not specific to the pneumoccocal vac-
cine. This result is important as it means that both vaccine involved these inflammatory path-
ways. This result was not obvious from the original analysis because their approach was less
powerful compared to TcGSA.
Assessment of statistical performances on simulated data
In order to assess the behavior of the proposed method, a simulation study of TcGSA has been
performed. The simulation scheme was chosen to be very close to the motivating exemple: the
DALIA-1 trial. In each simulation run, gene expression data was simulated for 20 patients at 8
time points. 5,000 genes were simulated, divided into 100 non overlapping gene sets of 50
genes each. Each of the 100 gene sets was either simulated under (H0) or (H1). The proportion
of genes under (H1) varied between 0%, 27% (which corresponds to results found in pre-ATI)
and 85% (which corresponds to results found in post-ATI). When there are gene sets simulated
under (H1), 75% of those were homogeneous (simulated with parameters close to those esti-
mated for gene set M1.2 in DALIA post-ATI—see Fig 4) while the remaining 25% were hetero-
geneous (simulated with parameters close to those estimated for gene set M7.1 in DALIA post-
ATI—see Fig 4).
Statistical performances of the proposed method are presented in Table 2. Without correct-
ing for the fact that 100 gene set were investigated by TcGSA at each simulation runs, the aver-
age Type I error (the probability of rejecting H0 given that H0 is actually true) over a hundred
runs was between 0.03 and 0.07 depending on the situation. But as soon as a control of the
FDR was used, the Type-I error rate dropped well below 1%, regardless of the flexibility of the
time function estimated (linear or cubic polynomials). The average statistical power (the prob-
ability of rejecting H0 given that H0 is actually false) is very good, always above 0.8 (dropping a
little bit after multiple testing correction as expected).
Three other methods were also evaluated on those simulations, namely globalANCOVA
[29] (using either permutations or an approximation to compute p-values), GSEA for time
series and CAMERA. Their statistical performances are also presented in Table 2. Type I error
is always well controlled by those three methods. However, both CAMERA and GSEA for time
series exhibit very low statistical power (as low as 10 times less than TcGSA after multiple test-
ing correction when there is a high proportion of significant gene sets). globalANCOVA,
whose global null hypothesis is not so different from the one tested in TcGSA, performs quite
well in terms of statistical power. Nonetheless it is still about 10% below TcGSA performances.
Those simulation results confirm that the higher number of selected gene sets by TcGSA in
the two real-life examples presented in this paper are mainly due to the increased power of
gene set analysis over gene-by-gene analysis (when repeated structure of the measurement is
properly accounted for), and not to a large number of false positives.
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Discussion
In this paper, we present a method to analyze repeated measurements of gene expression using
a gene set approach. Provided that the definition of the gene sets is relevant, this method helps
with detecting and interpreting subtle changes of gene expression over time. In our applica-
tions where the same definition of gene sets has been applied, we were able to compare the
response to several vaccines (against HIV, Influenza and Pneumococcus). Interestingly, we
found common pathways that were triggered by all three vaccines, mostly related to inflamma-
tion, as well as pathways specific to each vaccine.
The capacity of the proposed approach to detect subtle changes of gene expression is due to
two main factors: i) the use of a predefined gene sets that are functionally related ii) the use of
all available information, taking advantage of repeated measurements using mixed models.
Measurements of gene expression data in longitudinal studies may be missing because of
missed visits or poor quality of the samples, leading to unbalanced data. Missing at random
Table 2. Assessment of statistical performances through a simulation study.










0% TcGSA (linear) 0.0394 0.0002 - -
0% TcGSA (cubic) 0.0649 0.0004 - -
0% globalANCOVA (perm) 0.0483 0.0001 - -
0% globalANCOVA
(approx)
0.0006 0 - -
0% GSEA for time series 0 0 - -
0% CAMERA 0 0 - -
27% TcGSA (linear) - - 0.883 0.829
27% TcGSA (cubic) - - 0.882 0.810
27% globalANCOVA (perm) - - 0.787 0.706
27% globalANCOVA
(approx)
- - 0.660 0.510
27% GSEA for time series - - 0.459 0.214
27% CAMERA - - 0.374 0.109
85% TcGSA (linear) - - 0.885 0.847
85% TcGSA (cubic) - - 0.882 0.833
85% globalANCOVA (perm) - - 0.785 0.728
85% globalANCOVA
(approx)
- - 0.660 0.549
85% GSEA for time series - - 0.289 0.074
85% CAMERA - - 0.177 0.013
* Multiple Testing Correction: performed via Benjamini-Yekutieli procedure with a 5% threshold.
In each simulation, 100 gene sets are simulated and significance level α = 5% is applied. This table displays the Type I error and the statistical power
means over a hundred simulation runs for 3 different situations (0%, 27% and 85% of simulated gene sets are simulated under H1). Whenever the
percentage of gene sets simulated under H1 is not null, 25% of the gene sets simulated under H1 are heterogeneous, the remaining 75% being
homogeneous. Type I error is the probability of rejecting H0 given that H0 is true, i.e. for declaring a gene set significant when it actually is not. Statistical
power is the probability of rejecting H0 given that H1 is true, i.e. for declaring a gene set significant when it actually is. Four methods are evaluated: i)
TcGSA, the proposed approach, fitted either with a linear or with a cubic function of time; ii) the GlobalANCOVA procedure [29] in which p-values are
either computed by permutation (10,000) or approximated; iii) the GSEA for time series [14], iv) CAMERA [31]. Default values are used for the various
methods (see S1 Text and S1 Software).
doi:10.1371/journal.pcbi.1004310.t002
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(MAR) processes (i.e. when the probability of missing data is associated to the previously mea-
sured information) may lead to biased estimates when using least squares or generalized esti-
mating equations [37]. TcGSA can cope with such issues because of the use of Maximum
Likelihood to estimate the parameters of the mixed models. This is an advantage of the TcGSA
approach over those of Hummel et al. [29] or Nueda et al. [32].
An increasing number of gene sets databases are available, such as KEGG [11], Gene Ontol-
ogy [12], Modules [13]. An immune related subset of Gene Ontology as well as an immune
related subset of KEGG pathway have been used in additional analyses (see S3 Fig). The choice
of the database used for the analysis impacts the interpretability but also the limitations of
TcGSA. The efficiency of TcGSA will vary according to the number of genes represented in
each gene set. The size of a given gene set has an impact on its significance, as the more genes it
includes, the more likely a significant variation will be detected. The average size of the Chaus-
sabel’s V2 modules is 55 genes. 17% of the 260 modules include more than 100 genes, and 31%
less than 20 genes. For small gene sets, the normality assumptions of random effects of the Eqs
(1), (1bis) and (2) are questionable (even though inference should still be robust [59]). Never-
theless, even though we expect that the models could be misspecified in many cases (if not all),
the objective of such an analysis is to detect any significant variation over time (in the spirit of
Shahbaba et al. [19], a significant variability of the trajectories between the genes inside a gene
set indicates a change over time regardless of the fixed effects specification). The use of flexible
time functions may help to get a better fit of dynamics although beyond cubic polynomials it
did not have a substantial impact in our motivating example—see Table 1. These results vary
according to the dataset and the number of time points available, and we recommend to try
several models to check the robustness of the results.
TcGSA focuses on self-contained hypothesis. While competitive gene sets tests are appro-
priate in the presence of a strong signal (e.g. when comparing pre-ATI versus post-ATI), self-
contained approaches are able to detect more subtle and sparse signals (e.g in pre-ATI). The
choice between a competitive or a self-contained approach is therefore highly dependent on
the biological question.
Several extensions of the TcGSA are possible for its use in other contexts. One can also
model time trends with a random effect grouped on the patient level as of γp,, instead of on the
gene level as in Eqs (1), (1bis) and (2). This identifies gene sets whose dynamic differs across
the patients. This option is also implemented in the TcGSA R package. TcGSA could easily be
adapted to mRNA counts data. In that case, generalized linear mixed effects models could be
used, with a Poisson distribution for instance, instead of linear mixed effect models that rely on
a Gaussian assumption. Or else, precision weights estimated with voom [60] could also be used
to model the mean-variance relationship while fitting the proposed linear mixed effect directly
on log-counts data from RNA-seq, thus taking into account heteroscedasticity.
In conclusion, the method presented gives a solution for the full exploitation of any repeated
measurements of gene expression data based on a gene set analysis where a great sensibility to
detect subtle change, while controlling false discovery, is needed.
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S1 Fig. Density plot for both the 100,000 simulations under the null and a 100,000 sample
of the corresponding χ2 mixture approximation.
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S2 Fig. Quantile-quantile plot comparing the 100,000 simulations under the null to a
100,000 sample of the corresponding χ2 mixture approximation.
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S3 Fig. Comparison of TcGSA results on DALIA-1 trial data for the three gene sets data-
bases considered. During pre-ATI, 3 out of 75 gene sets were significant in the subset of
KEGG, and 0 out of 131 in the subset of GO. During post-ATI, 73 out of 75 gene sets were sig-
nificant in the subset of KEGG, and 101 out of 131 in the subset of GO. 2 gene sets the subset
of KEGG and 20 from the subset of GO were automatically discarded because less than 10
probes or more than 500 probes were observed.
(TIFF)
S1 Table. Selected KEGG pathways for investigating DALIA-1.Hand picked KEGG path-
ways [11] of interest for investigating DALIA-1 trial data.
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S2 Table. Selected GO pathways for investigating DALIA-1.Hand picked Gene Ontology
pathways [12] of interest for investigating DALIA-1 trial data.
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S1 File. The raw p-value and the adjusted false discovery rate—calculated with the Benja-
mini-Yiekutieli procedure—in pre-ATI in the DALIA-1 trial.
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S2 File. The raw p-value and the adjusted false discovery rate—calculated with the Benja-
mini-Yiekutieli procedure—in post-ATI in the DALIA-1 trial.
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S3 File. The raw p-value and the adjusted false discovery rate—calculated with the Benja-
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S4 File. The raw p-value and the adjusted false discovery rate—calculated with the Benja-
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